ClinicalTrials.gg
RecruitingNCT04664946Updated Sep 10, 2026

Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With No Reperfusion Therapy (INSIST-NRT)

An interventional study of Intra-arterial administration of neuroprotective agents in Ischemic Stroke and Neuroprotection, sponsored by Hui-Sheng Chen. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Hui-Sheng Chen · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2020; still recruiting 5 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 753 studies in Ischemic Stroke with a site in China — 380 open to participants now, 399 under way, 78 of them phase 3. Ischemic Stroke · China.

Planned enrollment
523rd of 565
30 · median 270
Started
2020
with 33 others
No phase
246 of 753
121 open now
Primary completion
2028-05
later than 309 of 398 live
Registered
188th of 753
by date

Among the 753 studies in Ischemic Stroke with a site in China, this one is the 523rd largest by planned enrollment of the 565 interventional ones that give a count, is one of 34 that started in 2020, is one of 246 with no phase, reaches primary completion later than 309 of the 398 other live ones, and was the 188th registered.

Ischemic Stroke

2,625 studies on the registry are indexed under Ischemic Stroke; 982 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

380 of the 753 studies in Ischemic Stroke with a site in China are open now. Recruiting first, the newest first:

375 more — sign in →

All 380 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 402 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 753 studies in Ischemic Stroke with a site in China, or all of them as a file.
02

Study summary

To explore the safety and feasibility of intra-arterial neuroprotective strategy in acute ischemic stroke patients who missed recanalization operation.

03

Conditions studied

  • Ischemic Stroke
  • Neuroprotection

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years;
  2. Major neurologic deficits: 6≤NIHSS≤20;
  3. Missing recanalization therapy (IVT or EVT) or progressive stroke, which was defined as symptoms worsen in 48 hours (an increase in NIHSS more than 4);
  4. Premorbid mRS 0 or 1;
  5. Signed .

Exclusion criteria

Exclusion Criteria:

  1. Modified Rankin Score >2 caused by a history of prior stroke;
  2. Patients who underwent intravenous thrombolysis or Endovascular treatment;
  3. Coagulation disorders, systematic hemorrhagic tendency, thrombocytopenia ( \<80000/mm3;
  4. Severe hepatic or renal dysfunction, increase in or AST (more than 2 times of value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis;
  5. Severe hypertension (systolic blood pressure over 200mmHg or diastolic blood pressure over 110 mmHg);
  6. Unsuitable for this clinical studies assessed by researcher.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Intra-arterial administration of 3-n-butylphthalide

    Intra-arterial administration of 3-n-butylphthalide for 24 hours via microcatheter at 17.36 ug/min.

    Drug: Intra-arterial administration of neuroprotective agents

Interventions

  • DrugIntra-arterial administration of neuroprotective agents

    Intra-arterial administration of 3-n-butylphthalide for 24 hours via microcatheter at 17.36 ug/min.

06

What researchers measure

Primary outcomes

  1. Proportion of server adverse events

    server adverse events including femoral artery dissection, local thrombosis, seudoaneurysm, arteriovenousfistula, etc.

    Time frame: 48 hours

Secondary outcomes

  1. Proportion of patients with modified Rankin Score 0 to 1

    Proportion of patients with modified Rankin Score 0 to 1

    Time frame: 90 days

  2. Proportion of patients with modified Rankin Score 0 to 2

    Proportion of patients with modified Rankin Score 0 to 2

    Time frame: 90 days

  3. Modified Rankin Score

    Modified Rankin Score

    Time frame: 90 days

  4. Decrease in national institutes of health stroke scale (NIHSS)

    Decrease in NIHSS scoring at 48 hours after the treatment

    Time frame: 48 hours

  5. Proportion of symptomatic intracranial hemorrhage (sICH)

    sICH was defined as 4 or more increase in NIHSS caused by hemorrhage

    Time frame: 48 hours

  6. Proportion of intraparenchymal hemorrhage (PH1 and PH2)

    Proportion of intraparenchymal hemorrhage (PH1 and PH2) within 48 hours after the treatment

    Time frame: 48 hours

  7. Changes in cerebral edema

    Cerebral edema was determined by cerebral volume or midline shift

    Time frame: 48 hours

  8. All causes of death within 48 hours after the treatment

    All causes of death within 48 hours after the treatment

    Time frame: 48 hours

  9. Differences in serum factors levels in different artery region

    Differences in serum factors levels in different Bessel region before recanalization

    Time frame: 0 hour

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2020 (actual). Primary completion is estimated for May 2028, 89 months after the start.

Of 574 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 89 months is above that.

Counting every sponsor, half of 655 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2020
First posted
Dec 11, 2020
StartActual
Dec 1, 2020
Primary completionEst.
May 1, 2028
CompletionEst.
May 1, 2028
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04664946
Lead sponsor
Hui-Sheng Chen
Responsible party
Hui-Sheng Chen (Director, General Hospital of Shenyang Military Region) — Sponsor-investigator
First posted
Dec 11, 2020
Start date
Dec 1, 2020
Primary completion
May 1, 2028 (estimated)
Completion
May 1, 2028 (estimated)
Last update
Sep 10, 2026

Study contacts

Hui-Sheng T Chen, Ph.D.
Contact
chszh@aliyun.com
+8613352452086

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion